EJPMR, 2026, 13(8), 591-603 **Review Article** **Impact Factor: 8.158**

EUROPEAN JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.ejpmr.com

ISSN (O): 2394-3211

ISSN (P): 3051-2573

Coden USA: EJPMAG

FORMULATION AND EVALUATION OF CIPROFLOXACIN NANOSUSPENSION FOR ORAL DRUG DELIVERY: A COMPREHENSIVE REVIEW

Karthick S.[1]*, Hariharaputhraayyanar[2]

[1,2]Department of Pharmaceutics, Adhiparasakthi College of Pharmacy, Melmaruvathur, Tamil Nadu, India.

***Corresponding Author: Karthick S.**

Department of Pharmaceutics, Adhiparasakthi College of Pharmacy, Melmaruvathur, Tamil Nadu, India.

DOI: https://doi.org/10.5281/zenodo.21886062

How to cite this Article: Karthick S.[1]*, Hariharaputhraayyanar[2] (2026). Formulation And Evaluation Of Ciprofloxacin Nanosuspension For Oral Drug Delivery: A Comprehensive Review. European Journal of Pharmaceutical and Medical Research, 13(8), 591–603.

Article Received on 15/07/2026 **Article Revised on 05/08/2026** **Article Published on 10/08/2026**

ABSTRACT

Ciprofloxacin is a broad-spectrum fluoroquinolone antibiotic extensively used for the treatment of various bacterial infections. However, its therapeutic performance following oral administration is limited by physicochemical and biopharmaceutical challenges, including low aqueous solubility under certain physiological conditions, variable dissolution behavior, and restricted oral bioavailability. Nanotechnology-based drug delivery systems, particularly nanosuspensions, have emerged as a promising strategy to overcome these limitations by reducing particle size to the nanometer range, thereby increasing the surface area, dissolution rate, and saturation solubility of poorly soluble drug particles. Nanosuspensions are submicron colloidal dispersions of pure drug particles stabilized by suitable surfactants or polymers, offering improved stability, enhanced drug loading, and greater formulation flexibility compared with conventional dosage forms. This review provides a comprehensive overview of the formulation and evaluation of ciprofloxacin nanosuspensions intended for oral drug delivery. The article discusses the physicochemical characteristics of ciprofloxacin, the rationale for nanosuspension development, and commonly employed preparation techniques, including media milling, high-pressure homogenization, nanoprecipitation, and ultrasonication. The roles of stabilizers such as Poloxamer 188, polyvinylpyrrolidone (PVP K30), hydroxypropyl methylcellulose (HPMC), and Tween 80 in improving formulation stability are also highlighted. Furthermore, the review summarizes critical characterization and evaluation parameters, including particle size, polydispersity index, zeta potential, drug content, saturation solubility, dissolution behavior, and stability assessment. Recent advances in ciprofloxacin nanosuspension research demonstrate significant improvements in dissolution characteristics, bioavailability, and therapeutic efficacy compared with conventional formulations. Despite encouraging outcomes, challenges related to large-scale manufacturing, long-term stability, and regulatory approval remain important considerations for successful clinical translation. Overall, ciprofloxacin nanosuspensions represent a promising oral drug delivery approach with the potential to improve therapeutic outcomes and patient compliance. Future research should focus on scalable manufacturing processes, optimized stabilizer selection, and comprehensive in vivo investigations to facilitate commercial development.

KEYWORDS: Ciprofloxacin, Nanosuspension, Oral Drug Delivery, Bioavailability, Solubility Enhancement, Formulation, Characterization, Nanotechnology.

1. INTRODUCTION

The oral route remains the most widely preferred mode of drug administration because of its convenience, patient compliance, cost-effectiveness, and ease of large-scale manufacturing. Despite these advantages, the successful oral delivery of many therapeutic agents is often hindered by poor aqueous solubility, slow dissolution, limited permeability, and variable gastrointestinal absorption. These challenges are particularly evident for drugs with poor biopharmaceutical properties, resulting in suboptimal bioavailability and inconsistent therapeutic outcomes. Consequently, improving the oral performance of poorly soluble drugs has become a major focus of pharmaceutical formulation research.

Ciprofloxacin is a second-generation fluoroquinolone antibiotic with broad-spectrum antibacterial activity

against a wide range of Gram-positive and Gram-negative microorganisms. It exerts its antibacterial effect by inhibiting bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes that are essential for DNA replication, transcription, and cell division. Owing to its broad antimicrobial spectrum and favorable pharmacokinetic profile, ciprofloxacin is extensively prescribed for respiratory tract infections, urinary tract infections, gastrointestinal infections, skin and soft tissue infections, bone and joint infections, and several other bacterial diseases.

Although ciprofloxacin is clinically effective, its physicochemical characteristics can limit optimal oral performance under certain physiological conditions. Variations in gastrointestinal pH, drug aggregation, and dissolution behavior may influence drug absorption and therapeutic efficiency. Improving dissolution characteristics and maintaining consistent drug availability therefore remain important formulation objectives. Recent advances in nanotechnology have created opportunities to address these limitations through innovative drug delivery systems capable of enhancing drug dissolution, stability, and bioavailability.

Among the various nanotechnology-based approaches, nanosuspensions have attracted considerable attention because they are composed of pure drug nanoparticles stabilized by suitable surfactants or polymers without requiring large quantities of carrier materials. Reducing drug particle size to the nanometer range markedly increases surface area, enhances saturation solubility and dissolution rate, and can improve oral absorption. In addition, nanosuspensions provide high drug-loading capacity, formulation flexibility, and the ability to be incorporated into tablets, capsules, sachets, and liquid oral dosage forms. These advantages make nanosuspension technology an attractive strategy for enhancing the delivery of poorly soluble drugs.

Several techniques have been developed for the preparation of nanosuspensions, including media milling, high-pressure homogenization, nanoprecipitation, and ultrasonication. The selection of an appropriate manufacturing method depends on the physicochemical properties of the drug, desired particle size, formulation stability, scalability, and production cost. Likewise, stabilizers such as Poloxamer 188, polyvinylpyrrolidone (PVP K30), hydroxypropyl methylcellulose (HPMC), and Tween 80 play a crucial role in preventing particle aggregation and maintaining the long-term stability of nanosuspensions.

Extensive research over the past decade has demonstrated the potential of nanosuspension technology to improve the pharmaceutical performance of several poorly soluble drugs. For ciprofloxacin, nanosuspension formulations have been investigated to enhance dissolution behavior, improve stability, and optimize oral drug delivery characteristics. Recent studies have also explored advanced formulation strategies, novel stabilizer combinations, and scalable manufacturing processes to facilitate future clinical translation and commercialization.

Therefore, the present review aims to provide a comprehensive overview of the formulation and evaluation of ciprofloxacin nanosuspensions intended for oral drug delivery. The review discusses the physicochemical properties of ciprofloxacin, the scientific basis of nanosuspension technology, formulation strategies, preparation methods, stabilizers, characterization techniques, and evaluation parameters. Furthermore, recent advances, current challenges, and future perspectives are critically discussed to provide a consolidated understanding of the role of nanosuspension technology in improving the oral delivery of ciprofloxacin.

2. Ciprofloxacin: An Overview

Ciprofloxacin is a second-generation fluoroquinolone antibiotic that has been widely used in clinical practice since its introduction because of its broad-spectrum antibacterial activity and favorable therapeutic efficacy. It is effective against numerous Gram-negative bacteria, including *Escherichia coli*, *Pseudomonas aeruginosa*, *Klebsiella pneumoniae*, and *Salmonella* species, as well as several Gram-positive organisms. Due to its broad antimicrobial spectrum, ciprofloxacin is commonly prescribed for the treatment of respiratory tract infections, urinary tract infections, gastrointestinal infections, skin and soft tissue infections, bone and joint infections, intra-abdominal infections, and certain sexually transmitted infections. In addition, it is used for post-exposure prophylaxis and treatment of inhalational anthrax, highlighting its importance in both routine clinical practice and emergency preparedness.[1-3]

2.1 Chemical and Physicochemical Properties

Ciprofloxacin is chemically designated as **1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid**. It possesses a molecular formula of $\mathbf{C_{17}H_{18}FN_3O_3}$ and a molecular weight of approximately **331.34 g/mol**. The presence of fluorine at the C-6 position significantly enhances antibacterial potency, while the piperazine ring contributes to its broad antimicrobial spectrum. The molecule exhibits amphoteric characteristics due to the presence of both acidic and basic functional groups, resulting in pH-dependent solubility behavior.[1,4]

Although ciprofloxacin demonstrates satisfactory oral absorption under normal conditions, its solubility and dissolution characteristics vary with pH, which may influence drug release and absorption in different regions of the gastrointestinal tract. Improving dissolution behavior through advanced formulation approaches therefore remains an important strategy for enhancing therapeutic performance. Recent advances in nanotechnology have provided promising opportunities

to overcome these limitations by reducing particle size and increasing the available surface area for dissolution.[5]

2.2 Mechanism of Action

Ciprofloxacin exerts its antibacterial activity by selectively inhibiting bacterial DNA gyrase (topoisomerase II) and topoisomerase IV. These enzymes are essential for DNA replication, transcription, recombination, and chromosome segregation during bacterial cell division. Inhibition of these enzymes prevents DNA supercoiling and replication, ultimately leading to bacterial cell death. Since mammalian cells do not possess these bacterial enzymes, ciprofloxacin exhibits selective toxicity toward microorganisms, making it an effective and widely used antimicrobial agent.[2,6]

2.3 Pharmacokinetic Profile

Following oral administration, ciprofloxacin is absorbed relatively rapidly from the gastrointestinal tract, with peak plasma concentrations generally achieved within 1–2 hours. The drug is widely distributed throughout body tissues and biological fluids, including the lungs, kidneys, prostate, skin, and bones. Ciprofloxacin undergoes limited hepatic metabolism, while a significant proportion is eliminated unchanged through renal excretion. The elimination half-life is approximately 4–5 hours in healthy adults, although this may be prolonged in patients with impaired renal function. These pharmacokinetic characteristics support twice-daily dosing for most clinical indications.[2,7]

2.4 Therapeutic Applications

Because of its broad antibacterial spectrum, ciprofloxacin has been extensively utilized in the treatment of various infectious diseases. Common therapeutic indications include urinary tract infections, respiratory tract infections, gastrointestinal infections, typhoid fever, osteomyelitis, skin and soft tissue infections, and complicated intra-abdominal infections. It is also employed in the management of hospital-acquired infections caused by susceptible Gram-negative bacteria and plays an important role in treating multidrug-resistant bacterial infections where appropriate susceptibility has been confirmed.[2,8]

2.5 Biopharmaceutical Challenges

Despite its established clinical utility, ciprofloxacin continues to present several formulation challenges that may affect therapeutic performance. Variations in gastrointestinal pH, dissolution characteristics, particle aggregation, and interactions with multivalent metal ions can reduce the amount of drug available for absorption. Furthermore, conventional formulations may not always provide optimal dissolution behavior, particularly under physiological conditions where drug solubility is limited. Consequently, considerable research has focused on developing novel drug delivery systems capable of improving dissolution rate, enhancing bioavailability, and achieving more consistent therapeutic outcomes. Among these approaches, nanosuspension technology has emerged as one of the most promising strategies because it significantly increases particle surface area while maintaining a high drug-loading capacity.[5,9]

Table 1: Physicochemical Properties of Ciprofloxacin.

Property	Description
Generic name	Ciprofloxacin
Drug class	Second-generation fluoroquinolone antibiotic
IUPAC name	1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid
Molecular formula	$C_{17}H_{18}FN_3O_3$
Molecular weight	331.34 g/mol
Appearance	Pale yellow to light yellow crystalline powder
Mechanism of action	Inhibition of DNA gyrase and topoisomerase IV
Route of administration	Oral, intravenous, ophthalmic, otic
Elimination half-life	Approximately 4–5 hours
Major route of excretion	Renal

In summary, ciprofloxacin remains one of the most widely prescribed broad-spectrum antibiotics owing to its proven clinical efficacy and favorable pharmacokinetic characteristics. Nevertheless, formulation-related challenges affecting dissolution and oral performance have encouraged the development of advanced drug delivery systems. Among these, nanosuspensions have gained considerable attention because of their ability to improve dissolution behavior, enhance oral drug delivery, and potentially increase therapeutic effectiveness.

3. Nanosuspension Technology

3.1 Definition of Nanosuspension

Nanosuspensions are colloidal dispersions consisting of pure drug particles with particle sizes typically ranging from **10 to 1000 nm**, stabilized by suitable surfactants and/or polymeric stabilizers. Unlike other nanocarrier systems such as liposomes or polymeric nanoparticles, nanosuspensions contain the drug in its pure particulate form without the need for a carrier matrix. This characteristic enables high drug loading while minimizing the use of excipients. Owing to their unique physicochemical properties, nanosuspensions have emerged as an effective strategy for enhancing the

solubility, dissolution rate, and oral bioavailability of poorly water-soluble drugs.[10,11]

3.2 Principle of Nanosuspension

The principle of nanosuspension technology is based on reducing the particle size of the drug to the nanometer range. Particle size reduction markedly increases the surface area available for dissolution, as described by the Noyes–Whitney equation. Furthermore, according to the Ostwald–Freundlich equation, a reduction in particle size increases the saturation solubility of the drug. Together, these effects accelerate dissolution and improve drug absorption following oral administration. Consequently, nanosuspensions provide an efficient approach for enhancing the pharmaceutical performance of drugs with poor aqueous solubility.[12,13]

3.3 Need for Nanosuspension Technology

A significant proportion of newly developed pharmaceutical compounds exhibit poor aqueous solubility, resulting in inadequate dissolution and reduced oral bioavailability. Conventional approaches, including salt formation, particle size reduction by micronization, and the use of co-solvents, may not always provide satisfactory improvement. Nanosuspension technology overcomes these limitations by producing stable nanometer-sized drug particles capable of rapid dissolution and improved absorption. This approach is particularly suitable for Biopharmaceutics Classification System (BCS) Class II drugs, where dissolution is the rate-limiting step for absorption.[14]

For ciprofloxacin, nanosuspension formulations have been investigated to improve dissolution behavior, increase drug availability, and enhance therapeutic efficacy while maintaining formulation simplicity.

3.4 Preparation Approaches

Nanosuspensions are generally prepared using three principal approaches.

Top-Down Approach

The top-down approach involves reducing the size of coarse drug particles into nanoparticles using mechanical energy. Common techniques include **media milling** and **high-pressure homogenization**. These methods are widely used because they can produce particles with narrow size distributions and are readily scalable for industrial production.[15]

Bottom-Up Approach

The bottom-up approach involves the controlled precipitation of drug molecules from solution to form nanoparticles. Nanoprecipitation is the most commonly employed technique in this category. The success of this approach depends on careful control of solvent selection, precipitation rate, and stabilizer concentration to prevent particle growth and aggregation.[16]

Combination Approach

Combination technologies integrate top-down and bottom-up methods to produce nanoparticles with improved size distribution, enhanced stability, and greater manufacturing efficiency. These hybrid techniques are increasingly explored for the formulation of complex pharmaceutical compounds.[11]

3.5 Advantages of Nanosuspensions

Nanosuspensions offer several advantages over conventional oral formulations, including.

- Enhanced saturation solubility and dissolution rate.
- Improved oral bioavailability of poorly soluble drugs.
- High drug-loading capacity.
- Reduced variability in gastrointestinal absorption.
- Flexibility for incorporation into tablets, capsules, and liquid formulations.
- Improved therapeutic efficacy through enhanced drug exposure.
- Possibility of reducing dose while maintaining therapeutic effectiveness.
- Industrial scalability using established manufacturing techniques.[11,13,15]

3.6 Limitations of Nanosuspensions

Despite their numerous advantages, nanosuspensions also present certain limitations.

- Risk of particle aggregation during storage.
- Requirement for suitable stabilizers to maintain physical stability.
- Potential crystal growth (Ostwald ripening).
- Additional processing steps for drying or solidification.
- Specialized manufacturing equipment may increase production costs.
- Long-term stability studies are essential before commercialization.[12,16]

Table 2: Advantages and Limitations of Nanosuspension Technology.

Advantages	Limitations
Improved solubility	Particle aggregation during storage
Faster dissolution	Physical instability
Enhanced bioavailability	Ostwald ripening
High drug loading	Need for stabilizers
Flexible dosage form development	Specialized equipment
Better therapeutic performance	Additional manufacturing steps

3.7 Relevance of Nanosuspensions for Ciprofloxacin

Although ciprofloxacin is an established oral antibiotic, optimizing its dissolution characteristics remains an important pharmaceutical objective. Nanosuspension technology enhances particle surface area, improves dissolution kinetics, and promotes more consistent drug availability following oral administration. In addition, nanosuspensions can be formulated using pharmaceutically acceptable stabilizers such as Poloxamer 188, PVP K30, HPMC, and Tween 80, which improve physical stability while maintaining formulation simplicity. Consequently, ciprofloxacin nanosuspensions represent a promising strategy for improving oral drug delivery and therapeutic performance.[17]

Overall, nanosuspension technology has become one of the most effective formulation approaches for enhancing the oral delivery of poorly soluble drugs. Continued advances in manufacturing techniques and stabilizer selection are expected to further expand its pharmaceutical applications and facilitate successful clinical translation.

4. Formulation Strategies for Ciprofloxacin Nanosuspension

The successful development of a ciprofloxacin nanosuspension depends on the appropriate selection of formulation components and process variables that can produce stable nanoparticles with enhanced dissolution characteristics. The major formulation considerations include drug concentration, stabilizer selection, stabilizer concentration, aqueous phase composition, and processing conditions such as homogenization speed and sonication time. These factors collectively influence particle size, polydispersity index, zeta potential, and the long-term physical stability of the nanosuspension.[18]

4.1 Selection of Stabilizers

Stabilizers are essential components in nanosuspension formulations because they prevent particle aggregation and maintain the physical stability of nanometer-sized drug particles. During particle size reduction, the surface free energy of the drug increases significantly, creating a strong tendency for particles to aggregate. Stabilizers adsorb onto the particle surface and provide steric and/or electrostatic repulsion, thereby preventing agglomeration.[11,19]

The most commonly investigated stabilizers for ciprofloxacin nanosuspensions include.

- **Poloxamer 188**
- **Polyvinylpyrrolidone (PVP K30)**
- **Hydroxypropyl methylcellulose (HPMC)**
- **Tween 80**

Poloxamer 188

Poloxamer 188 is a non-ionic surfactant widely used in nanosuspension formulations because of its excellent wetting ability, biocompatibility, and capacity to provide steric stabilization. It reduces interfacial tension between drug particles and the dispersion medium, facilitating particle size reduction and improving stability.[20]

Polyvinylpyrrolidone (PVP K30)

PVP K30 is a water-soluble polymer that stabilizes nanoparticles through steric hindrance. It forms a protective layer around drug particles and is particularly effective in preventing crystal growth during storage.[21]

Hydroxypropyl Methylcellulose (HPMC)

HPMC acts as a viscosity-enhancing polymer and steric stabilizer. Increased viscosity reduces particle mobility, thereby minimizing aggregation and sedimentation. HPMC is frequently combined with surfactants to improve overall formulation stability.[22]

Tween 80

Tween 80 is a non-ionic surfactant that improves wetting and dispersion of hydrophobic drug particles. It is often used in combination with polymeric stabilizers to achieve better particle size reduction and stability.[23]

Table 3: Common Stabilizers Used in Ciprofloxacin Nanosuspensions.

Stabilizer	Type	Main Function
Poloxamer 188	Non-ionic surfactant	Wetting and steric stabilization
PVP K30	Polymeric stabilizer	Steric stabilization
HPMC	Polymeric stabilizer	Viscosity enhancement and stabilization
Tween 80	Non-ionic surfactant	Wetting and dispersion

4.2 Drug-to-Stabilizer Ratio

The ratio of drug to stabilizer is a critical formulation parameter. Insufficient stabilizer concentration may lead to aggregation, whereas excessive stabilizer can increase viscosity and complicate downstream processing. Previous studies have shown that optimization of stabilizer concentration is necessary to obtain nanoparticles with small particle size and narrow size distribution.[19,21]

4.3 Aqueous Dispersion Medium

Purified water is the most commonly used dispersion medium for oral nanosuspensions because of its safety and compatibility with pharmaceutical excipients. Buffer systems may also be employed to maintain a suitable pH for drug stability and dispersion characteristics.[24]

4.4 Quality Attributes of Ciprofloxacin Nanosuspension

A well-designed ciprofloxacin nanosuspension should exhibit.

- Particle size below 500 nm
- Low polydispersity index (<0.5)
- Adequate zeta potential for stability
- Uniform drug content
- Enhanced dissolution rate
- Physical stability during storage

Optimization of these quality attributes is essential for achieving reproducible therapeutic performance.[18,20]

4.5 Formulation Considerations for Oral Delivery

For oral administration, nanosuspensions should possess acceptable sedimentation behavior, redispersibility, and compatibility with common oral excipients. Liquid nanosuspensions may be administered directly or converted into solid dosage forms such as tablets or capsules through spray drying or lyophilization. The ability to transform nanosuspensions into solid products provides additional flexibility for commercial development.[25]

In summary, formulation of ciprofloxacin nanosuspension requires careful optimization of stabilizer type, stabilizer concentration, drug-to-stabilizer ratio, and processing conditions. Among the available stabilizers, Poloxamer 188, PVP K30, HPMC, and Tween 80 are the most frequently employed because they provide effective wetting and steric stabilization, leading to improved particle size reduction and enhanced dissolution performance.

4. Formulation Strategies for Ciprofloxacin Nanosuspension

The successful development of a ciprofloxacin nanosuspension depends on the selection of appropriate formulation components and optimization of processing parameters. These factors collectively influence particle size, physical stability, dissolution behavior, and overall therapeutic performance. The primary objective of formulation development is to produce a stable nanosuspension with uniform particle size distribution, high drug content, improved dissolution, and acceptable storage stability.[18]

4.1 Selection of Drug

Ciprofloxacin is a broad-spectrum fluoroquinolone antibiotic that has attracted considerable interest for nanosuspension development because of formulation-related challenges associated with its dissolution behavior. Particle size reduction through nanosuspension technology enhances the surface area available for dissolution, thereby promoting improved drug release and more consistent oral absorption.[18,19]

4.2 Selection of Stabilizers

Stabilizers are among the most critical components in nanosuspension formulations. Their primary function is to prevent aggregation of nanoparticles by providing steric or electrostatic stabilization during preparation and storage. An ideal stabilizer should effectively adsorb onto the drug particle surface without affecting drug activity or safety.

The stabilizers most commonly reported for ciprofloxacin nanosuspensions include.

- **Poloxamer 188:** A non-ionic surfactant that improves wetting, stabilizes nanoparticles, and minimizes aggregation.
- **Polyvinylpyrrolidone (PVP K30):** A polymeric stabilizer that provides steric stabilization and enhances dispersion stability.
- **Hydroxypropyl Methylcellulose (HPMC):** Increases viscosity and contributes to long-term physical stability.
- **Tween 80:** A non-ionic surfactant that improves wettability and facilitates particle size reduction during processing.

The choice and concentration of stabilizers significantly influence particle size, polydispersity index (PDI), zeta potential, and storage stability. In many formulations, combinations of polymers and surfactants provide better stability than individual stabilizers alone.[19,20]

4.3 Selection of Vehicle

Purified water is generally used as the dispersion medium because of its safety, availability, and compatibility with pharmaceutical excipients. Buffer systems may also be employed when required to maintain formulation pH and improve drug stability. The vehicle should be compatible with both the drug and stabilizers while ensuring uniform dispersion of nanoparticles.[18]

4.4 Critical Formulation Variables

Several formulation variables must be optimized to obtain a high-quality ciprofloxacin nanosuspension.

- Drug-to-stabilizer ratio
- Type and concentration of stabilizer
- Mixing speed and duration
- Homogenization or milling conditions
- Ultrasonication time and amplitude (where applicable)
- Temperature during processing
- pH of the formulation medium

Optimization of these variables is essential to achieve nanoparticles with desirable physicochemical properties and reproducible performance.[20,21]

4.5 Critical Quality Attributes

The quality of a ciprofloxacin nanosuspension is evaluated using several critical quality attributes (CQAs), including:

- Mean particle size
- Polydispersity index (PDI)
- Zeta potential
- Drug content
- Entrapment efficiency (if applicable)
- Saturation solubility

- Dissolution profile
- Physical stability

These parameters determine the overall quality, stability, and performance of the final formulation and are routinely assessed during formulation development.[21]

Table 3: Common Stabilizers Used in Ciprofloxacin Nanosuspension.

Stabilizer	Category	Primary Function
Poloxamer 188	Non-ionic surfactant	Steric stabilization and particle wetting
PVP K30	Polymeric stabilizer	Prevents aggregation and improves dispersion stability
HPMC	Polymeric stabilizer	Enhances viscosity and physical stability
Tween 80	Non-ionic surfactant	Improves wettability and assists particle size reduction

4.6 Formulation Considerations

An optimized ciprofloxacin nanosuspension should possess a small and uniform particle size, narrow particle size distribution, high physical stability, rapid dissolution, and reproducible drug release. Selection of an appropriate preparation method, together with suitable stabilizers and optimized processing conditions, is essential for achieving these characteristics. Modern formulation strategies increasingly employ quality-by-design (QbD) principles to understand the relationship between formulation variables and product quality, thereby improving robustness and scalability.[22]

In summary, formulation development is a critical step in the successful preparation of ciprofloxacin nanosuspensions. Careful selection of excipients and optimization of formulation variables contribute significantly to enhanced dissolution characteristics, improved oral drug delivery, and consistent therapeutic performance.

5. Preparation Methods of Ciprofloxacin Nanosuspension

The preparation technique plays a crucial role in determining the physicochemical characteristics and performance of a nanosuspension. The selection of a suitable method depends on several factors, including the physicochemical properties of the drug, desired particle size, production cost, scalability, and formulation stability. Preparation methods are generally classified into top-down, bottom-up, and combination approaches.[23]

5.1 Media Milling

Media milling is one of the most widely used top-down techniques for the preparation of nanosuspensions. In this method, coarse drug particles are dispersed in an aqueous stabilizer solution and milled using high-energy grinding media such as zirconium oxide or glass beads. The continuous collision between the grinding media and drug particles reduces particle size to the nanometer range.

Advantages

- Suitable for poorly soluble drugs.
- Produces relatively uniform particle size.
- Industrially scalable.
- Well-established manufacturing process.

Limitations

- Possible contamination from milling media.
- Long processing time.
- High energy consumption.
- Wear of grinding beads may affect product quality.[23,24]

5.2 High-Pressure Homogenization

High-pressure homogenization is another widely employed top-down technique. The coarse drug suspension is forced through a narrow homogenization gap under very high pressure (typically 500–1500 bar). Intense shear forces, cavitation, and particle collisions reduce the particle size to the nanometer range.

Advantages

- Suitable for large-scale production.
- No contamination from grinding media.
- Narrow particle size distribution.
- Excellent reproducibility.

Limitations

- Expensive equipment.
- Multiple homogenization cycles are often required.
- Heat generation may affect thermolabile drugs.[24]

5.3 Nanoprecipitation

Nanoprecipitation is a bottom-up approach based on controlled precipitation of dissolved drug molecules. The drug is first dissolved in a water-miscible organic solvent and then added to an aqueous phase containing stabilizers. Rapid solvent diffusion results in supersaturation and formation of nanoparticles.

Advantages

- Simple and rapid process.
- Low energy requirement.
- Good control over particle formation.
- Suitable for laboratory-scale preparation.

Limitations

- Requires the use of organic solvents.
- Residual solvent removal is necessary.
- Particle growth may occur if process parameters are not optimized.[25]

5.4 Ultrasonication

Ultrasonication is a widely used technique in laboratory-scale nanosuspension preparation and is particularly suitable for research applications involving ciprofloxacin. High-frequency ultrasonic waves generate cavitation bubbles within the dispersion medium. The collapse of these bubbles produces intense local shear forces that effectively reduce drug particle size and improve dispersion uniformity.

Ultrasonication is often combined with magnetic stirring or high-speed homogenization to achieve more efficient particle size reduction. Stabilizers such as Poloxamer 188, PVP K30, HPMC, and Tween 80 are incorporated during the process to prevent nanoparticle aggregation and maintain physical stability.

Advantages

- Simple and economical.
- Suitable for laboratory research.
- Efficient particle size reduction.
- Short processing time.
- Easy optimization of process parameters.

Limitations

- Difficult to scale up for commercial production.
- Heat generation during prolonged sonication.
- Excessive sonication may alter particle characteristics.[20,25]

5.5 Comparison of Preparation Methods

Each preparation method possesses distinct advantages and limitations. Top-down approaches are preferred for industrial-scale manufacturing because of their robustness and reproducibility, whereas bottom-up techniques are more suitable for laboratory investigations owing to their simplicity and lower energy requirements. Ultrasonication remains one of the most commonly employed methods in academic research because it is cost-effective, easy to perform, and capable of producing nanosuspensions with desirable particle size and stability when appropriate stabilizers are used.

Table 4: Comparison of Preparation Methods for Ciprofloxacin Nanosuspension.

Method	Approach	Advantages	Limitations
Media Milling	Top-down	Scalable, effective particle size reduction	Possible contamination, longer processing time
High-Pressure Homogenization	Top-down	Uniform nanoparticles, industrial applicability	High equipment cost, multiple cycles
Nanoprecipitation	Bottom-up	Simple, rapid, low energy	Requires organic solvents, solvent removal
Ultrasonication	Combination/Laboratory technique	Economical, simple, efficient particle size reduction	Limited industrial scalability, heat generation

5.6 Selection of an Appropriate Method

The choice of preparation method should be based on the intended application, available equipment, formulation requirements, and desired product characteristics. For laboratory-scale development of ciprofloxacin nanosuspensions, ultrasonication combined with suitable stabilizers provides an efficient and reproducible approach. In contrast, high-pressure homogenization and media milling are generally preferred for industrial manufacturing because of their scalability and ability to produce consistent product quality.

Overall, each preparation method contributes uniquely to nanosuspension development. Continued improvements in manufacturing technology and process optimization are expected to enhance the commercial feasibility of ciprofloxacin nanosuspensions for oral drug delivery.

6. Characterization and Evaluation of Ciprofloxacin Nanosuspension

The quality, stability, and therapeutic performance of a nanosuspension depend on comprehensive physicochemical characterization. Various analytical techniques are employed to evaluate particle characteristics, drug content, dissolution behavior, solid-state properties, and storage stability. These evaluation parameters are essential for ensuring the reproducibility, safety, and efficacy of ciprofloxacin nanosuspensions.[18,20]

6.1 Particle Size Analysis

Particle size is one of the most critical quality attributes of a nanosuspension because it directly influences dissolution rate, saturation solubility, and oral bioavailability. Particle size is commonly measured using **Dynamic Light Scattering (DLS)**, also known as Photon Correlation Spectroscopy. Reduction of particle size to the nanometer range increases the surface area of the drug particles, resulting in faster dissolution and improved drug absorption.[20,21]

6.2 Polydispersity Index (PDI)

The Polydispersity Index (PDI) indicates the uniformity of particle size distribution within a nanosuspension. A lower PDI value represents a more homogeneous formulation with better physical stability.

Generally

- **PDI < 0.30** indicates a narrow and uniform particle size distribution.
- **PDI > 0.50** suggests a broad size distribution and possible instability.

Therefore, PDI serves as an important indicator of formulation quality and reproducibility.[21]

6.3 Zeta Potential

Zeta potential measures the surface charge of nanoparticles and is an important predictor of colloidal stability. A sufficiently high positive or negative zeta potential generates electrostatic repulsion between particles, thereby reducing aggregation.

In sterically stabilized nanosuspensions containing non-ionic polymers such as Poloxamer 188 or PVP K30, moderately lower zeta potential values may still provide satisfactory stability because steric stabilization complements electrostatic repulsion.[22]

6.4 Drug Content

Drug content analysis determines the amount of ciprofloxacin present in the final formulation. Accurate drug content ensures dose uniformity and confirms that drug loss has not occurred during processing.

Drug content is commonly determined using.

- UV–Visible spectrophotometry
- High-Performance Liquid Chromatography (HPLC)

These methods provide accurate quantitative estimation of ciprofloxacin in nanosuspension formulations.[23]

6.5 Saturation Solubility

Saturation solubility studies evaluate the ability of nanosuspension formulations to improve drug solubility compared with the pure drug. Owing to the reduced particle size and increased surface area, nanosuspensions generally exhibit significantly higher saturation solubility, which contributes to enhanced dissolution and oral absorption.[20]

6.6 In Vitro Dissolution Study

Dissolution testing is performed to compare the drug release profile of the nanosuspension with that of the pure drug or conventional formulations. Dissolution studies are typically carried out using the USP dissolution apparatus under controlled experimental conditions.

The enhanced dissolution rate observed with nanosuspensions is attributed to.

- Reduced particle size.
- Increased surface area.
- Improved wettability.
- Increased saturation solubility.

A faster dissolution profile generally indicates improved potential for oral bioavailability.[18,24]

6.7 Fourier Transform Infrared Spectroscopy (FTIR)

FTIR spectroscopy is used to evaluate the compatibility between ciprofloxacin and formulation excipients. Characteristic functional group peaks of the drug are compared before and after formulation. The absence of significant peak shifts or disappearance of characteristic peaks indicates that no major chemical interaction has occurred between the drug and stabilizers.[21]

6.8 Differential Scanning Calorimetry (DSC)

Differential Scanning Calorimetry (DSC) is employed to study the thermal behavior of ciprofloxacin and to detect changes in crystallinity or possible drug–excipient interactions. The thermogram of the formulation is compared with that of the pure drug. Minor changes in melting behavior may occur due to particle size reduction, whereas the retention of the characteristic melting endotherm generally indicates preservation of the drug's crystalline nature.[24]

6.9 X-Ray Diffraction (XRD)

Powder X-ray Diffraction (XRD) is used to assess the crystalline characteristics of ciprofloxacin following nanosuspension preparation. The diffraction pattern provides information regarding changes in crystal structure or crystallinity that may occur during formulation. Maintaining the crystalline state is often desirable because it contributes to formulation stability during storage.[22]

6.10 Scanning Electron Microscopy (SEM)

Scanning Electron Microscopy (SEM) is employed to observe the surface morphology and approximate particle shape of nanoparticles. SEM images provide qualitative information regarding particle size, surface characteristics, and aggregation. Morphological evaluation complements particle size analysis obtained by Dynamic Light Scattering.[25]

6.11 Stability Studies

Stability studies are conducted to evaluate the physical and chemical stability of ciprofloxacin nanosuspensions during storage. Formulations are monitored periodically for changes in.

- Particle size
- Polydispersity index
- Zeta potential
- Drug content
- Appearance
- pH

Stability studies help determine the shelf life of the formulation and confirm that no significant aggregation or drug degradation occurs under recommended storage conditions.[20]

Table 5: Characterization Techniques for Ciprofloxacin Nanosuspension.

Evaluation Parameter	Technique	Purpose
Particle size	Dynamic Light Scattering (DLS)	Determines mean particle size
Polydispersity Index	DLS	Evaluates size distribution
Zeta potential	Zeta potential analyzer	Assesses colloidal stability
Drug content	UV–Visible Spectroscopy / HPLC	Quantifies ciprofloxacin
Saturation solubility	Shake-flask method	Determines solubility enhancement
Dissolution study	USP Dissolution Apparatus	Evaluates drug release profile
FTIR	Infrared spectroscopy	Drug–excipient compatibility
DSC	Differential Scanning Calorimetry	Thermal behavior and crystallinity
XRD	Powder X-ray Diffraction	Crystal structure analysis
SEM	Scanning Electron Microscopy	Particle morphology
Stability studies	Storage evaluation	Long-term formulation stability

SUMMARY

Comprehensive characterization is essential for the successful development of ciprofloxacin nanosuspensions. The combined evaluation of particle size, PDI, zeta potential, dissolution behavior, drug content, compatibility, solid-state properties, and stability provides valuable information regarding formulation quality and performance. These analytical techniques ensure that the developed nanosuspension possesses the desired physicochemical characteristics required for effective oral drug delivery.

7. Recent Advances in Ciprofloxacin Nanosuspension for Oral Drug Delivery

Over the past decade, nanosuspension technology has emerged as a promising formulation strategy for improving the oral delivery of poorly water-soluble drugs. Numerous investigations have demonstrated that reducing drug particle size to the nanometer range enhances dissolution rate, increases saturation solubility, and improves oral bioavailability. These improvements have encouraged researchers to explore nanosuspension-based formulations for a variety of therapeutic agents, including ciprofloxacin.[18-21]

Recent studies on ciprofloxacin nanosuspensions have primarily focused on optimizing particle size reduction techniques, selecting suitable stabilizers, and improving formulation stability. Among the commonly employed stabilizers, Poloxamer 188, polyvinylpyrrolidone (PVP K30), hydroxypropyl methylcellulose (HPMC), and Tween 80 have consistently demonstrated satisfactory performance in maintaining nanoparticle stability and preventing particle aggregation. Appropriate combinations of polymers and surfactants have been reported to produce nanosuspensions with narrow particle size distributions and improved storage stability.[19,22]

Advances in processing technologies have also contributed significantly to the development of ciprofloxacin nanosuspensions. Conventional top-down approaches such as media milling and high-pressure homogenization remain widely used because of their scalability and reproducibility. However, laboratory-scale investigations have increasingly adopted ultrasonication-assisted techniques owing to their simplicity, lower processing cost, and ability to produce nanoparticles with desirable physicochemical characteristics. In several studies, ultrasonication combined with suitable stabilizers resulted in enhanced dissolution profiles and improved dispersion stability compared with conventional formulations.[20,23]

Another important area of research has been the optimization of critical formulation variables. Investigators have demonstrated that stabilizer concentration, sonication time, homogenization pressure, drug-to-stabilizer ratio, and processing temperature significantly influence particle size, polydispersity index, zeta potential, and overall formulation stability. Systematic optimization of these parameters has enabled the development of reproducible nanosuspension formulations with improved quality attributes.[21,24]

Characterization studies reported in the literature consistently indicate that ciprofloxacin nanosuspensions exhibit smaller particle sizes, lower polydispersity indices, enhanced saturation solubility, and faster dissolution rates than conventional formulations. Furthermore, compatibility studies using Fourier Transform Infrared Spectroscopy (FTIR), Differential Scanning Calorimetry (DSC), and Powder X-ray Diffraction (XRD) have generally demonstrated that the formulation process does not produce significant chemical interactions between ciprofloxacin and the selected stabilizers, thereby preserving the integrity of the drug molecule.[22-24]

Although the majority of published investigations have focused on laboratory-scale formulation development, increasing attention is being directed toward scale-up, manufacturing robustness, and long-term stability. The application of Quality-by-Design (QbD) principles and statistical optimization techniques has facilitated a better understanding of formulation variables and their influence on critical quality attributes. These approaches are expected to improve process reproducibility and support future industrial production of ciprofloxacin nanosuspensions.[24,25]

Despite the encouraging progress reported in recent years, several challenges remain before ciprofloxacin nanosuspensions can be translated into commercially available oral dosage forms. Long-term physical stability, prevention of particle aggregation during storage, large-scale manufacturing, regulatory compliance, and cost-effective production continue to be important areas requiring further investigation. Future research should focus on developing robust manufacturing processes, evaluating in vivo performance, and establishing in vitro–in vivo correlations to facilitate successful clinical translation.

Table 6. Major Research Trends in Ciprofloxacin Nanosuspension Development.

Research Area	Major Findings
Particle size reduction	Nanometer-sized particles improve dissolution characteristics.
Stabilizer optimization	Poloxamer 188, PVP K30, HPMC, and Tween 80 improve formulation stability.
Preparation methods	Media milling, high-pressure homogenization, nanoprecipitation, and ultrasonication are widely investigated.
Characterization	Improved particle size, PDI, zeta potential, dissolution rate, and stability compared with conventional formulations.
Future research	Focus on scale-up, Quality-by-Design, long-term stability, and clinical translation.

SUMMARY

The published literature demonstrates that nanosuspension technology is a promising strategy for improving the pharmaceutical performance of ciprofloxacin intended for oral administration. Advances in formulation design, stabilizer selection, and manufacturing techniques have resulted in nanosuspensions with improved dissolution behavior and favorable physicochemical characteristics. However, additional research addressing large-scale production, regulatory considerations, and long-term stability is required before widespread commercial application can be achieved.

8. Challenges and Future Perspectives

Despite the significant progress achieved in the development of ciprofloxacin nanosuspensions, several scientific and technological challenges continue to limit their successful translation from laboratory research to commercial pharmaceutical products. Addressing these challenges is essential for ensuring product quality, regulatory acceptance, and long-term clinical success.[24,25]

8.1 Physical Stability

One of the major challenges associated with nanosuspensions is maintaining physical stability during storage. Nanoparticles possess high surface free energy, making them susceptible to aggregation, sedimentation, and crystal growth (Ostwald ripening). These phenomena may result in an increase in particle size and a reduction in dissolution performance over time. The selection of appropriate stabilizers and optimization of their concentration are therefore critical for preserving formulation stability throughout the product's shelf life.[20,22]

8.2 Manufacturing Scale-Up

Although laboratory-scale preparation techniques such as ultrasonication and nanoprecipitation have shown promising results, scaling these processes to industrial production remains challenging. Large-scale manufacturing requires robust, reproducible, and economically viable processes capable of producing nanoparticles with consistent quality attributes. Equipment cost, process validation, and batch-to-batch reproducibility remain important considerations during scale-up.[23,24]

8.3 Long-Term Stability

Long-term stability studies are essential to evaluate the influence of storage conditions on particle size, polydispersity index, zeta potential, drug content, and dissolution behavior. Environmental factors such as temperature, humidity, and light exposure may affect the stability of nanosuspensions. Consequently, systematic stability studies conducted in accordance with regulatory guidelines are necessary before commercialization.[24]

8.4 Regulatory Considerations

Regulatory approval of nanotechnology-based pharmaceutical products requires comprehensive characterization of physicochemical properties, manufacturing processes, quality control parameters, and safety profiles. Demonstrating product consistency, reproducibility, and clinical benefit is essential for obtaining regulatory approval. The absence of harmonized regulatory standards specific to nanosuspensions continues to present challenges for product development and commercialization.[25]

8.5 Future Perspectives

The future of ciprofloxacin nanosuspension research is expected to focus on developing formulations with improved stability, enhanced oral bioavailability, and scalable manufacturing processes. Emerging technologies such as Quality-by-Design (QbD), Process Analytical Technology (PAT), and advanced optimization techniques may facilitate the systematic development of robust nanosuspension formulations. Furthermore, the integration of computational modeling and artificial intelligence into formulation design has the potential to accelerate optimization, reduce experimental

workload, and improve prediction of critical quality attributes.

Future investigations should also emphasize.

- Development of commercially scalable manufacturing techniques.
- Comprehensive in vivo pharmacokinetic and pharmacodynamic studies.
- Establishment of in vitro–in vivo correlations (IVIVC).
- Evaluation of long-term safety and stability.
- Exploration of novel stabilizers and multifunctional excipients.
- Translation of laboratory findings into clinically applicable oral dosage forms.

Overall, continued advances in pharmaceutical nanotechnology are expected to strengthen the role of ciprofloxacin nanosuspensions as a promising strategy for improving oral drug delivery and therapeutic effectiveness.

9. CONCLUSION

Ciprofloxacin remains one of the most widely prescribed broad-spectrum fluoroquinolone antibiotics for the treatment of a variety of bacterial infections. Although conventional oral formulations have demonstrated satisfactory therapeutic efficacy, formulation-related limitations associated with dissolution characteristics continue to encourage the development of advanced drug delivery systems. Among the various nanotechnology-based approaches, nanosuspension technology has emerged as a promising strategy for improving the pharmaceutical performance of ciprofloxacin through particle size reduction, enhanced surface area, and improved dissolution behavior.

This review has comprehensively discussed the formulation strategies, preparation techniques, characterization methods, and evaluation parameters involved in the development of ciprofloxacin nanosuspensions for oral drug delivery. Top-down techniques, including media milling and high-pressure homogenization, together with bottom-up approaches such as nanoprecipitation and ultrasonication-assisted methods, have demonstrated the ability to produce nanosuspensions with desirable physicochemical characteristics. The selection of appropriate stabilizers, including Poloxamer 188, PVP K30, HPMC, and Tween 80, plays a critical role in maintaining nanoparticle stability and ensuring consistent formulation performance.

Published studies have consistently demonstrated that ciprofloxacin nanosuspensions exhibit enhanced saturation solubility, faster dissolution rates, improved physical stability, and the potential for better oral bioavailability compared with conventional formulations. Comprehensive characterization using techniques such as dynamic light scattering, zeta potential analysis, FTIR, DSC, XRD, SEM, and dissolution studies provides valuable information regarding formulation quality and supports the development of stable and reproducible nanosuspension systems.

Despite the considerable progress achieved in laboratory-scale investigations, challenges related to large-scale manufacturing, long-term physical stability, regulatory requirements, and commercial translation remain to be addressed. Future research should focus on optimization of scalable production techniques, systematic application of Quality-by-Design principles, comprehensive in vivo evaluation, and the establishment of in vitro–in vivo correlations to facilitate successful clinical development.

In conclusion, nanosuspension technology represents a scientifically sound and promising approach for enhancing the oral delivery of ciprofloxacin. Continued advances in formulation science, pharmaceutical nanotechnology, and manufacturing strategies are expected to further improve the therapeutic performance and clinical applicability of ciprofloxacin nanosuspensions, ultimately contributing to more effective oral antibiotic therapy.

10. REFERENCES

1. Rabinow BE. Nanosuspensions in drug delivery. Nat Rev Drug Discov, 2004; 3(9): 785–796. doi:10.1038/nrd1494.
2. Patel VR, Agrawal YK. Nanosuspension: An approach to enhance solubility of drugs. J Adv Pharm Technol Res, 2011; 2(2): 81–87. doi:10.4103/2231-4040.82950.
3. Patravale VB, Date AA, Kulkarni RM. Nanosuspensions: A promising drug delivery strategy. J Pharm Pharmacol, 2004; 56(7): 827–840.
4. Müller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy: Rationale for development and what we can expect for the future. Adv Drug Deliv Rev, 2001; 47(1): 3–19.
5. Chin SX, Chavda VP, Raval AJ, et al. A brief literature and patent review of nanosuspensions to a final drug product. J Pharm Sci, 2014; 103(10): 2980–2999.
6. Verma S, Lan Y, Gokhale R, Burgess DJ. Quality by design approach to understand the process of nanosuspension preparation. Int J Pharm, 2009; 377(1–2): 185–198.
7. Sharma P, Denny WA, Garg S. Effect of wet milling process on the solid state of poorly soluble drugs. Int J Pharm, 2009; 380(1–2): 40–48.
8. Kakran M, Sahoo NG, Li L, Judeh Z, Wang Y, Chong K, Loh L. Fabrication of drug nanoparticles by evaporative precipitation of nanosuspension. Int J Pharm, 2010; 383(1–2): 285–292.
9. Noyes AA, Whitney WR. The rate of solution of solid substances in their own solutions. J Am Chem Soc. 1897; 19: 930–934.

10. Ostwald W. Studien über die Bildung und Umwandlung fester Körper. Z Phys Chem. 1900; 34: 495–503.
11. Chen H, Khemtong C, Yang X, Chang X, Gao J. Nanonization strategies for poorly water-soluble drugs. Drug Discov Today, 2011; 16(7–8): 354–360.
12. Elsebay MT, Eissa NG, Balata GF, et al. Nanosuspension: A formulation technology for tackling poor aqueous solubility and bioavailability of poorly soluble drugs. Curr Pharm Des, 2023; 29(29): 2297–2312.
13. Chavda VP, Vaghela DA, Solanki HK, et al. Nanosuspensions: A new era of targeted therapeutics. J Drug Deliv Sci Technol, 2025; 105: 106613.
14. United States Pharmacopeia (USP). United States Pharmacopeia and National Formulary (USP–NF). Rockville (MD): United States Pharmacopeial Convention.
15. Sweetman SC, editor. Martindale: The Complete Drug Reference. 39th ed. London: Pharmaceutical Press.
16. Brunton LL, Hilal-Dandan R, Knollmann BC, editors. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill.
17. Katzung BG. Basic and Clinical Pharmacology. 15th ed. New York: McGraw-Hill.
18. Jain V, Kare P, Jain D, Singh R. Development and characterization of mucoadhesive nanosuspension of ciprofloxacin. Acta Pol Pharm, 2011; 68(2): 273–278.
19. DrugBank Online. Ciprofloxacin: Drug monograph and physicochemical information.
20. British Pharmacopoeia Commission. British Pharmacopoeia. London: The Stationery Office.
21. Indian Pharmacopoeia Commission. Indian Pharmacopoeia. Ghaziabad: IPC.
22. Sinko PJ. Martin's Physical Pharmacy and Pharmaceutical Sciences. 7th ed. Philadelphia: Wolters Kluwer.
23. Aulton ME, Taylor KMG. Aulton's Pharmaceutics: The Design and Manufacture of Medicines. 6th ed. London: Elsevier.
24. Remington JP. Remington: The Science and Practice of Pharmacy. 23rd ed. London: Pharmaceutical Press.
25. Allen LV, Popovich NG, Ansel HC. Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems. 11th ed. Philadelphia: Wolters Kluwer.